Novel endogenous peptide agonists of cannabinoid receptors

Ivone Gomes, Julia S. Grushko, Urszula Golebiewska, Sascha Hoogendoorn, Achla Gupta, Andrea S. Heimann, Emer S. Ferro, Suzanne Scarlata, Lloyd D. Fricker, Lakshmi A. Devi

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Hemopressin (Hp), a 9-residue α-hemoglobin-derived peptide, was previously reported to function as a CB1 cannabinoid receptor antagonist (1). In this study, we report that mass spectrometry (MS) data from peptidomics analyses of mouse brain extracts identified N-terminally extended forms of Hp containing either three (RVD-Hpα) or two (VD-Hpα) additional amino acids, as well as a β-hemoglobin-derived peptide with sequence similarity to that of hemopressin (VD-Hpβ). Characterization of the α-hemoglobin-derived peptides using binding and functional assays shows that in contrast to Hp, which functions as a CB1 cannabinoid receptor antagonist, both RVD-Hpα and VD-Hpα function as agonists. Studies examining the increase in the phosphorylation of ERK1/2 levels or release of intracellular Ca2+ indicate that these peptides activate a signal transduction pathway distinct from that activated by the endocannabinoid, 2-arachidonoylglycerol, or the classic CB1 agonist, Hu-210. This finding suggests an additional mode of regulation of endogenous cannabinoid receptor activity. Taken together, these results suggest that the CB1 receptor is involved in the integration of signals from both lipid- and peptide-derived signaling molecules.

Original languageEnglish (US)
Pages (from-to)3020-3029
Number of pages10
JournalFASEB Journal
Volume23
Issue number9
DOIs
StatePublished - Sep 2009

Fingerprint

Cannabinoid Receptor Agonists
Peptides
Cannabinoid Receptor Antagonists
Hemoglobins
hemopressin
Cannabinoid Receptor CB1
Cannabinoid Receptors
Endocannabinoids
Signal transduction
Phosphorylation
Mass spectrometry
Assays
Signal Transduction
Brain
Mass Spectrometry
Lipids
Amino Acids

Keywords

  • Analgesia
  • Drug abuse
  • G-protein-coupled receptors
  • Pain

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Genetics
  • Molecular Biology

Cite this

Gomes, I., Grushko, J. S., Golebiewska, U., Hoogendoorn, S., Gupta, A., Heimann, A. S., ... Devi, L. A. (2009). Novel endogenous peptide agonists of cannabinoid receptors. FASEB Journal, 23(9), 3020-3029. https://doi.org/10.1096/fj.09-132142

Novel endogenous peptide agonists of cannabinoid receptors. / Gomes, Ivone; Grushko, Julia S.; Golebiewska, Urszula; Hoogendoorn, Sascha; Gupta, Achla; Heimann, Andrea S.; Ferro, Emer S.; Scarlata, Suzanne; Fricker, Lloyd D.; Devi, Lakshmi A.

In: FASEB Journal, Vol. 23, No. 9, 09.2009, p. 3020-3029.

Research output: Contribution to journalArticle

Gomes, I, Grushko, JS, Golebiewska, U, Hoogendoorn, S, Gupta, A, Heimann, AS, Ferro, ES, Scarlata, S, Fricker, LD & Devi, LA 2009, 'Novel endogenous peptide agonists of cannabinoid receptors', FASEB Journal, vol. 23, no. 9, pp. 3020-3029. https://doi.org/10.1096/fj.09-132142
Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS et al. Novel endogenous peptide agonists of cannabinoid receptors. FASEB Journal. 2009 Sep;23(9):3020-3029. https://doi.org/10.1096/fj.09-132142
Gomes, Ivone ; Grushko, Julia S. ; Golebiewska, Urszula ; Hoogendoorn, Sascha ; Gupta, Achla ; Heimann, Andrea S. ; Ferro, Emer S. ; Scarlata, Suzanne ; Fricker, Lloyd D. ; Devi, Lakshmi A. / Novel endogenous peptide agonists of cannabinoid receptors. In: FASEB Journal. 2009 ; Vol. 23, No. 9. pp. 3020-3029.
@article{5809a1f8d8684adc9de2c23aa7004b2d,
title = "Novel endogenous peptide agonists of cannabinoid receptors",
abstract = "Hemopressin (Hp), a 9-residue α-hemoglobin-derived peptide, was previously reported to function as a CB1 cannabinoid receptor antagonist (1). In this study, we report that mass spectrometry (MS) data from peptidomics analyses of mouse brain extracts identified N-terminally extended forms of Hp containing either three (RVD-Hpα) or two (VD-Hpα) additional amino acids, as well as a β-hemoglobin-derived peptide with sequence similarity to that of hemopressin (VD-Hpβ). Characterization of the α-hemoglobin-derived peptides using binding and functional assays shows that in contrast to Hp, which functions as a CB1 cannabinoid receptor antagonist, both RVD-Hpα and VD-Hpα function as agonists. Studies examining the increase in the phosphorylation of ERK1/2 levels or release of intracellular Ca2+ indicate that these peptides activate a signal transduction pathway distinct from that activated by the endocannabinoid, 2-arachidonoylglycerol, or the classic CB1 agonist, Hu-210. This finding suggests an additional mode of regulation of endogenous cannabinoid receptor activity. Taken together, these results suggest that the CB1 receptor is involved in the integration of signals from both lipid- and peptide-derived signaling molecules.",
keywords = "Analgesia, Drug abuse, G-protein-coupled receptors, Pain",
author = "Ivone Gomes and Grushko, {Julia S.} and Urszula Golebiewska and Sascha Hoogendoorn and Achla Gupta and Heimann, {Andrea S.} and Ferro, {Emer S.} and Suzanne Scarlata and Fricker, {Lloyd D.} and Devi, {Lakshmi A.}",
year = "2009",
month = "9",
doi = "10.1096/fj.09-132142",
language = "English (US)",
volume = "23",
pages = "3020--3029",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "9",

}

TY - JOUR

T1 - Novel endogenous peptide agonists of cannabinoid receptors

AU - Gomes, Ivone

AU - Grushko, Julia S.

AU - Golebiewska, Urszula

AU - Hoogendoorn, Sascha

AU - Gupta, Achla

AU - Heimann, Andrea S.

AU - Ferro, Emer S.

AU - Scarlata, Suzanne

AU - Fricker, Lloyd D.

AU - Devi, Lakshmi A.

PY - 2009/9

Y1 - 2009/9

N2 - Hemopressin (Hp), a 9-residue α-hemoglobin-derived peptide, was previously reported to function as a CB1 cannabinoid receptor antagonist (1). In this study, we report that mass spectrometry (MS) data from peptidomics analyses of mouse brain extracts identified N-terminally extended forms of Hp containing either three (RVD-Hpα) or two (VD-Hpα) additional amino acids, as well as a β-hemoglobin-derived peptide with sequence similarity to that of hemopressin (VD-Hpβ). Characterization of the α-hemoglobin-derived peptides using binding and functional assays shows that in contrast to Hp, which functions as a CB1 cannabinoid receptor antagonist, both RVD-Hpα and VD-Hpα function as agonists. Studies examining the increase in the phosphorylation of ERK1/2 levels or release of intracellular Ca2+ indicate that these peptides activate a signal transduction pathway distinct from that activated by the endocannabinoid, 2-arachidonoylglycerol, or the classic CB1 agonist, Hu-210. This finding suggests an additional mode of regulation of endogenous cannabinoid receptor activity. Taken together, these results suggest that the CB1 receptor is involved in the integration of signals from both lipid- and peptide-derived signaling molecules.

AB - Hemopressin (Hp), a 9-residue α-hemoglobin-derived peptide, was previously reported to function as a CB1 cannabinoid receptor antagonist (1). In this study, we report that mass spectrometry (MS) data from peptidomics analyses of mouse brain extracts identified N-terminally extended forms of Hp containing either three (RVD-Hpα) or two (VD-Hpα) additional amino acids, as well as a β-hemoglobin-derived peptide with sequence similarity to that of hemopressin (VD-Hpβ). Characterization of the α-hemoglobin-derived peptides using binding and functional assays shows that in contrast to Hp, which functions as a CB1 cannabinoid receptor antagonist, both RVD-Hpα and VD-Hpα function as agonists. Studies examining the increase in the phosphorylation of ERK1/2 levels or release of intracellular Ca2+ indicate that these peptides activate a signal transduction pathway distinct from that activated by the endocannabinoid, 2-arachidonoylglycerol, or the classic CB1 agonist, Hu-210. This finding suggests an additional mode of regulation of endogenous cannabinoid receptor activity. Taken together, these results suggest that the CB1 receptor is involved in the integration of signals from both lipid- and peptide-derived signaling molecules.

KW - Analgesia

KW - Drug abuse

KW - G-protein-coupled receptors

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=70349339642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349339642&partnerID=8YFLogxK

U2 - 10.1096/fj.09-132142

DO - 10.1096/fj.09-132142

M3 - Article

C2 - 19380512

AN - SCOPUS:70349339642

VL - 23

SP - 3020

EP - 3029

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 9

ER -